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Background: Hypoglycemia secondary to ectopic insulin secretion of non-pancreatic tumors is rare.
Case presentation: We describe a middle aged woman with recurrent hypoglycemia. On evaluation, she was detected
to have hyperinsulinemic hypoglycemia and right sided renal mass lesion. 68Ga-Dotanoc and 99mTc-HYNICTOC scans
confirmed the intrarenal mass to be of neuroendocrine origin. Right nephrectomy was done and it turned out to be an
insulin secreting neuroendocrine tumour. Neuroendocrine nature of this tumour was further confirmed by ultra-structural
examination. Her hypoglycemia did not recur after resection of this tumour.
Conclusion: Few cases of ectopic insulin secretion have been reported though some are not proven convincingly. This
case addresses all the issues raised in previous case reports and proves by clinical, laboratory, functional imaging and
immunohistochemical analysis that ectopic origin of insulin by non-pancreatic tumors does occur. To our knowledge, this
is the first reported case of ectopic insulinoma arising from the kidney.
Keywords: Hyperinsulinemic hypoglycemia, Neuroendocrine tumour, Insulinoma, Carcinoid tumor, Renal tumour,
68Ga-Dotanoc scan, 99mTc-HYNICTOC scanBackground
The most common cause of endogenous hypoglycemia is
hyperinsulinemia secondary to islet cell tumours of pan-
creas. Hypoglycemia due to non-pancreatic tumours is in-
frequently reported. Most of these non-pancreatic tumours
secrete factors with insulin like activity. Ectopic insulin se-
cretion has been reported in few cases but not convincingly
proved. We report a case of ectopic insulin secretion by
neuroendocrine tumour (NET) of kidney. The ectopic ori-
gin of the tumour is demonstrated by functional imaging
(68Ga-Dotanoc and 99mTc-HYNICTOC), and by immuno-
histochemistry for insulin staining. We also extensively
reviewed literature for similar cases of ectopic insulin se-
creting tumours published previously.* Correspondence: vivekapjyotsna@yahoo.com
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This 44-year- old female was admitted for evaluation of
recurrent hypoglycemic episodes of 3 years duration.
She had complains of forgetfulness, altered behaviour,
headache, palpitation, sweating, and giddiness. Most of
her symptoms occurred early in the morning and these
symptoms improved spontaneously in 15 minutes. She
had consulted various physicians including neurologist
and psychiatrist and had been diagnosed as pseudo-
seizure, panic attacks or conversion disorder. One year
back, she consulted endocrinologist and was diagnosed
to have hypoglycemia and hyperinsulinemia. For sus-
pecting insulinoma, she underwent CT abdomen which
showed a right renal mass lesion and possibility of renal
cell carcinoma was entertained. She was advised surgery
for renal tumour. However, patient did not agree for
surgery. There were no complains of hematuria, urinary
frequency, urgency, burning micturition, diarrhoea ortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and was not hypertensive. For last 2 months, patient
was having recurrent hypoglycemic seizures and came
to this hospital.
After admission, she had persisted hypoglycemia and re-
quired continuous infusion of 10% Dextrose at the rate of
75 – 100 ml/hr in addition to 1-2 hourly feeds. Her hemo-
gram, electrolytes, renal and liver functions were normal.
HbA1c was 4.5%. Hormonal assay showed thyroxine (T4)
5.67 (5.1 – 14.1 mcg/dl), TSH 4.42 (0.27 – 4.2 mIU/ml),
Insulin like Growth Factor- I(IGF-1) - 165.90 (62 –
205 ng/ml), growth hormone 1.20 ng/ml and cortisol
15.78 mcg/dl. Samples collected during hypoglycemia
showed a serum insulin of 134 (2.6 – 24.9 μU/ml) and
C-peptide of 13.35 (1.1 – 4.4) ng/ml. During another
symptomatic hypoglycemia, she had plasma glucose of
44 mg/dl while her plasma insulin and C-peptide were
49.81 miu/ml and 9.36 ng/ml respectively confirming
endogenous hyperinsulinemic hypoglycemia. She under-
went high resolution radiological and functional imaging
for localisation of insulinoma.
Both multi-phase CT abdomen (Figure 1) and contrast
enhanced MRI abdomen demonstrated a mass lesion aris-
ing from upper- mid pole of right kidney (Figure 1a, 1b,
1c). No lesion was identified in the pancreas (Figure 1d).
Endoscopic ultrasound also did not demonstrate any pan-
creatic lesion. 68Gallium DOTANOC scan (Figure 2a-c)
and 99mTc-HYNICTOC (Figure 2d,e) did not demon-
strate any uptake in the pancreas but both demonstrated
intense uptake in the mass lesion indicating a NET. She
underwent abdominal exploration and right nephrectomy.Figure 1 CT scan. Unenhanced CT axial image (1a) showing an isodense
arterial phase image (1b) but lesser than the renal cortex. The enhanceme
taken at the level of pancreas (arrow) did not show any arterial enhancingPost-operative period was uneventful and she became
euglycemic without need for dextrose infusion. Her glu-
cose values were maintained between 120 – 160 mg/dl
thus confirming the right sided mass near renal hilum to
be the source of ectopic insulin secretion.
Pathologic examination
Gross examination: Grossly the kidney measured
10×7×6 cm and weighed 350 gram. A solid well circum-
scribed yellowish tumour, measuring 7×6×5 cm, was identi-
fied in the upper pole of kidney (Figure 3a). There was no
capsule breach or renal sinus infiltration. Rest of the renal
parenchyma and pelvicalyceal system were unremarkable.
Areas of necrosis or hemorrhage were not identified.
Microscopic Finding: Microscopically, the tumor was
composed of solid nests anastomosing cords and trabecu-
lae of low columnar cells separated by a vascular stroma
[Figures 3b-d]. The cellular outlines were indistinct with
centrally placed oval nuclei, fine chromatin and incon-
spicuous nucleoli. The cytoplasm was eosinophilic, finely
granular and moderate in amount. At places there were
intense desmoplasia around the tumor cells (Figure 3e).
Mitotic rate was 1 per 10 high power fields (hpf). Areas of
tumour necrosis were not identified. Foci of perineural,
lymphatic and vascular invasion were not seen. No intra or
extra-cellular mucin was identified. Immunohistochemical
staining revealed diffuse and intense staining for pancyto-
keratin, synaptophysin, chromogranin A, neuron specific
enolase (NSE) and insulin (Figure 3f, 3g, 3h). MIB I labeling
index was 2% (Figure 3i). The lymph nodes dissected from
the specimen show metastasis (2/3).mass (arrow) to renal parenchyma which show enhancement in
nt continued till the venous phase (1c). Arterial phase image (1d)
lesion.
Figure 2 Nuclear scans. 3 mCi of 68Ga-Dotanoc PET/CT scan demonstrates somatostatin receptor (SSTR) expressing an intrarenal mass (2a) that
corresponds to NCCT mass (2b). There was no abnormal SSTR expressing tumour in pancreas (2c), or any other abdominal structure. Similar
observation was initially made from 15 mCi of 99mTc-HYNICTOC SPECT/CT scanning (2d, 2e).
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dense, membrane bound round to oval shaped granules of
variable diameter in the cytoplasm [Figure 3j, 3k]. A narrow
peripheral lighter zone was present in some of the granules.
Based on the above features; the diagnosis neuroendo-
crine tumour grade G1; pathological stage IV was enter-
tained. Serum chromogranin A measured in the samples
collected before surgery and stored in -40 degree was
2126.1 (N < 90.1 ng/ml).
Follow up
No metastasis was detected. Our patient got discharged in
stable condition on 10th post-operative day. The patient is
asymptomatic, euglycemic and disease free at last follow-
up at 3 months.
Discussion
Islet cell tumours of pancreas produce insulin which cause
hypoglycemia. Hypoglycemia due to non-pancreatic tumours
is infrequently reported and poorly understood. Various
mechanisms were proposed [1] are: (a) insulin or
insulin-like activity produced by the tumour, (b) de-
creased gluconeogenesis, (c) disruption of glucagon me-
tabolism, and (d) increased utilization of glucose by the
tumour. The non-suppressible Insulin like Activity
(NSILA) has been purposed to be secondary to Insulin
like Growth Factor-2. The non-islet cell tumours whichcommonly cause hypoglycaemia are of mesenchymal,
epithelial or hematopoietic cell lines. Fibrosarcomas,
mesotheliomas, leiomyosarcomas, and hemangiopericy-
tomas are the most frequent types of tumours which
cause hypoglycemia. Hepatoma, gastric, pancreatic, exo-
crine gland and lung carcinomas are epithelial cancers
with frequent hypoglycemic potential. Mesenchymal
and epithelial tumors, which generally present as large
masses, are located in the mediastinum or the abdomen.
These tumours are known to cause hypoglycemia via se-
cretion of IGF-2 that leads to stimulation of insulin recep-
tors [2]. In a series of 78 cases of non-islet-cell tumour,
hypoglycemia (NICTH) due to IGF-2 production, hepato-
cellular carcinoma and gastric carcinoma were the com-
mon causes [3].
Ectopic insulin secreting tumours are rare, comprising
only 1% to 2% of all insulinomas [4] and are commonly lo-
cated in the peripancreatic or periduodenal region where
most heterotopic pancreatic tissue is located. Ectopic in-
sulin producing tumours located away from pancreatic
beds are infrequently reported in literature. Only few
cases were described in literature due to hyperinsuline-
mic hypoglycemia and non-pancreatic tumour and
these tumors are described in Table 1.
The patient under discussion had presented with right
renal mass lesion and hyperinsulinemic hypoglycemia.
We initially considered the possibility of incidentally
Figure 3 Histopathology. Gross photomicrograph showing a yellow colored well circumscribed tumour in the upper pole of the kidney (3a).
Photomicrographs showing diffuse and trabecular arrangement of tumour cells (3b, 3c & 3d) with marked desmoplastic reaction at places (3e).
(3b, 3c & 3d: H&E × 400 each, 3e: H&E × 200). Tumour cells are immunoreactive to chromogranin, synaptophysin and insulin (3f, 3g, 3h × 400
each). MIB 1 LI is 2% (d3i × 200). Electron micrographs showing numerous membrane bound electron dense neurosecretory granules,
mitochondria and prominent rough endoplasmic reticulum (3j × 2550; 3k × 9000 original magnification).
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noma. In our Institute, we have both PET and SPECT
imaging agents for octreoscan available for the localisa-
tion of insulinoma. Somatostain receptor scintigraphy
(SRS) is an established functional imaging method for pa-
tients with NETs. The sensitivity of SRS for insulinoma
is 50 – 60% [12]. We did both 68Ga-Dotanoc and 99mTc-
HYNICTOC scans for the localisation of insulinoma which
unexpectedly revealed increased uptake in the right renal
mass lesion itself confirming it to be a NET. To the best
of our knowledge, this is the first case of ectopic insulin
secretion confirmed in vivo by 68Ga-Dotanoc and 99mTc-
HYNICTOC scan. Further, the neuroendocrine and insulin
secreting nature of the tumour was confirmed ex vivo by
histopathological examination, immunohistochemistry and
ultra-structural examination. Paraganglioma and pheochro-
moctyoma were also reported to cause hyperinsulinemic
hypoglycemia and also show tracer uptake by SRS and are
immunoreactive for chromogranin A and syanptophysin.
Though the mass lesion was arising from upper pole of
right kidney, it was intra-renal and hisopathological exam-
ination was suggestive of NET.
NETs are neoplasms that arise from cells of dispersed
neuroendocrine system. Although there are many kinds of
NETs but they are treated as a group of tumours as these
neoplasms share common features such as histology,immunoreactivity for neuroendocrine markers (chromo-
granin A, synaptophysin, neuron specific enolase), pres-
ence of neurosecretory granules, and secretion of biogenic
amines and polypeptide hormones. Neuroendocrine tu-
mours arising from pancreas are classified by the hormone
most commonly secreted. Neuroendocrine tumours aris-
ing from the intestine, respiratory system and rest of the
body were known as carcinoids but under the recent no-
menclature they are all know as neuroendocrine neoplasm
(NEN) of tumour. Primary carcinoid tumours of kidney
are extremely rare and around 90 cases has been reported
in literature [13]. None of the reported cases including
two cases were reported from our institute previously
[14, 15] were insulin secreting.
The cell of origin of renal carcinoid is unclear as neuro-
endocrine cells are not normally found in adult renal pa-
renchyma. Carcinoid tumours of kidney are usually
asymptomatic. In symptomatic cases, these tumours present
with abdominal pain or abdominal mass with hematuria or
fever. Evidence of carcinoid syndrome with serotonin-
related flushing, generalized edema and diarrhoea,
and occasional elevation of urine 5-hydroxyindoleaceticacid
are uncommon and are seen in less than 10% of cases [14].
Our patient did not have these symptoms prior to presenta-
tion, although she had flushing, edema and blanching of the
skin intraoperatively. Rarely, these tumours may present
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vipoma, or glucagonoma [16]. Our case presented as
insulinoma. Macroscopically, renal carcinoid tumours are
usually solitary and unilateral. They are well circum-
scribed with a lobulated and bulging appearance. The cut
surface the tumour is yellow-tan, or red brown as also
observed in the case under discussion. Renal carcinoids
exhibit histological features that are typical of carcinoids
at other sites. Primary carcinoid tumors as well as me-
tastasis possess high affinity receptors for somatostatin
in 87% of cases [17]. Localization of gastrointestinal
tract carcinoid tumours and pancreatic endocrine tu-
mors has been achieved by the use of radiolabeled
octreotide, a synthetic and slowly degraded somato-
statin analogue that has a high affinity for somatostatin
receptors. Use of indium-111 pentetreotide scanning in
the diagnosis of carcinoid tumors had been reported
[18]. In the present case, functional imaging with 68Ga-
Dotanoc and 99mTc-HYNICTOC was done for the local-
isation of insulinoma. Both showed uptake in the right
renal mass lesion and no uptake in pancreas (Figure 2a-e).
All available modalities for diagnosis of carcinoid tumors
were employed namely Electron microscopy, immunohis-
tochemistry, both PET and SPECT octreotide scan along
with conventional radiographic imaging techniques were







1 Ovarian carcinoid [5] Insulin staining (5%), EM – beta
cell granules, absence of
pancreatic tumor at autopsy
Not d
2 Carcinoma cervix [6] Insulin staining, absence of
pancreatic tumor at autopsy
Not d
3 Bronchial carcinoid [7] Insulin staining Not d
4 Paraganglioma [8] None Yes
5 Paraganglioma [9] Insulin staining (3%) Yes
6 Pheochromocytoma [10] Insulin stain negative, absence




Insulin staining, absence of any
extrahepatic tumor at autopsy,






EM – beta cell granules,
Yes
aIncludes evidences other than biochemical documentation of hyperinsulinemia in
bLiver functions are reportedly normal in this patient.
c70% of the liver was replaced by tumor at autopsy in this patient.
dThis patient developed hypoglycemia after left hepatectomy.
HPE – Histo-pathological examination, EM – Electron Microscopy.Prognosis of NET depends upon the grade and stage
of the tumour. Although the grade of the tumour was
low, however stage was high as there was metastasis in
the regional lymph nodes. There was no recurrence of
hypoglycaemia on till this time of reporting, however,
long-term close follow up is needed for the malignant
behaviour.Conclusions
Ectopic insulin secreting extra-pancreatic tumours are
rare. Confirmation of the source of hyperinsulinemia is
often difficult. To our knowledge, this is the first case
of extra-pancreatic insulin secreting neuroendocrine
tumour fully characterised by biochemical, radiological &
functional imaging, histopathology and immunohisto-
chemistry. Our patient had successful post-operative out-
come and maintained euglycaemia after three months of
follow-up.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for








emonstrated HPE Direct tumoral secretion of
insulin
emonstrated HPE Liver metastasisb, Direct
tumoral secretion of insulin
emonstrated HPE Liver metastasisc, Direct
tumoral secretion of insulin
HPE No conclusive evidence of
direct tumoral secretion
of insulin
HPE Direct tumoral secretion
of insulin
emonstrated HPE Beta adrenoceptor
mediated release of
insulin from pancreas







critical samples(collected at the time of hypoglycemia).
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